BRAF Mutation in Albanian Melanoma Patients New Approach from Diagnosis to the Treatment
Abstract
The incidence of cutaneous melanoma is steadily increasing, mainly in populations of European origin and is thus an important public health issue throughout the world. Cutaneous melanoma is a malignancy with a favorable prognosis if it presents as a localized disease, but with a dramatically worse prognosis if it metastasizes. No effective treatment exists for the group of melanoma patients with metastasizing disease, although several nonspecific chemotherapy regimens and immunotherapies are able to prolong survival at least for a short period of time. Last years has started a new area in the treatment using BRAF mutation inhibitors, especially for patients with BRAF V600E positive, so, also in melanoma is available targeted therapy. This new treatment plays an important role in their survival. The aim of the study: to evaluate the BRAF mutation in patients diagnosed with melanoma. Methods: We analised BRAF mutation in 12 formaline -fixed paraffine embedded (FFPE) tissue of patients diagnosed with melanoma from January to December 2014. Results: From 12 FFPE tissue we found 67 % (n=8) BRAF V600E, 25 % (n=3) BRAF Wild Type, 8% (n=1) BRAF V600K. Conclusions: BRAF V600E mutation is an important molecular target for novel therapeutic approaches in area of targeted therapy of melanoma patients. Patient with unresectable or metastatic melanoma, whith BRAF V600E, can use BRAF – inhibitors, increasing their survival.
Keywords: Albania, melanoma, BRAF mutation, biopsy.
Downloads
Published
How to Cite
Issue
Section
License
Declaration/Copyright transfer:
1. In consideration of the undertaking set out in paragraph 2, and upon acceptance by ANGLISTICUM for publication of the manuscript in the Journal, I/We hereby assign and transfer publication rights to ANGLISTICUM, whereas I/We retain the copyright for the manuscript. This assignment provides ANGLISTICUM the sole right and responsibility to publish the manuscript in its printed and online version, and/or in other media formats.
2. In consideration of this assignment, ANGLISTICUM hereby undertakes to prepare and publish the manuscript in the Journal, subject only to its right to refuse publication if there is a breach of the Author’s warranty in paragraph 4 or if there are other reasonable grounds.
3. Editors and the editorial board of ANGLISTICUM are empowered to make such editorial changes as may be necessary to make the Manuscript suitable for publication.
4. I/We hereby acknowledge that: (a) The manuscript submitted is an original work and that I/We participated in the work substantively and thus I/We hereby are prepared to take public responsibility for the work; (b) I/We hereby have seen and approved the manuscript as submitted and that the manuscript has not either been published, submitted or considered for publication elsewhere; (c) The text, illustration, and any other materials included in the manuscript do not infringe upon any existing copyright or other rights of anyone.
5. I/We hereby indemnify ANGLISTICUM and the respective Editors of the Journal as mentioned in paragraph 3, and hold them harmless from any loss, expense or damage occasioned by a claim or suit by a third party for copyright infringement, or any suit arising out of any breach of the foregoing warranties as a result of publication of the manuscript.